Laryngeal Dystonia, New Approaches for Direct Botulinum Toxin Administration

Luis Javier López Del Val; José Miguel Sebastián Cortes; Elena Bellosta Diago; Sonia Santos Lasaosa; Paúl Ricardo Vinueza Buitron; Yolanda Lois Ortega; Héctor Valles Varea; Elena López García

doi:doi:10.11648/j.ajpn.20190703.11

Laryngeal Dystonia, New Approaches for Direct Botulinum Toxin Administration

Luis Javier López Del Val, José Miguel Sebastián Cortes, Elena Bellosta Diago, Sonia Santos Lasaosa, Paúl Ricardo Vinueza Buitron, Yolanda Lois Ortega, Héctor Valles Varea, Elena López García

Published in American Journal of Psychiatry and Neuroscience (Volume 7, Issue 3)

Received: 27 June 2019 Accepted: 12 August 2019 Published: 29 August 2019

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

To describe our experience in the treatment of laryngeal dystonia (in abduction and adduction), with special emphasis given to the technical aspects (approach procedure, dosage and type of botulinum toxin type A used), as well as treatment response and possible side effects. We conducted a cross-sectional descriptive study of a sample of patients with laryngeal dystonia treated by means of transoral administration of onabotulinumtoxinA or incobotulinumtoxinA over a period of 10 years (2007-2017). Data collected include demographic and clinical variables, treatment response (based on a self-rating scale), the duration of treatment and the appearance of side effects. Sample size: 15 patients (11 women; mean age: 44.06 years) with laryngeal dystonia (mean time since onset of 40 months; 12 patients with dystonia in adduction) and 174 administrations (92% incobotulinumtoxinA; average dosage of 5 U in each vocal cord). The procedure took an average of 11.7 minutes to perform. Response was good in 31% of the procedures and very good in 57.5%. Side effects were recorded in 14.4% of the procedures, although always mild and transitory, with a predominance of dysphagia and dysphonia. In our experience, transoral administration of botulinum toxin type A to treat laryngeal dystonia has proved to be a simple, quick, effective and safe technique.

Published in	American Journal of Psychiatry and Neuroscience (Volume 7, Issue 3)
DOI	10.11648/j.ajpn.20190703.11
Page(s)	52-56
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2019. Published by Science Publishing Group

Keywords

Botulinum Toxin A, Incobotulinumtoxin, Dystonia, Laryngeal Dystonia, Therapeutic Administration

References

[1]	Tarsy D, Simon DK. Dystonia. N Engl J Med 2006; 355: 818-29.
[2]	L. J. López del Val, et al of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope 1988; 98: 193-7.
[3]	Critchley M. Spastic dysphonia (‘inspiratory speech’). Brain. 1939; 62: 96-103.
[4]	Jankovic J, Fahn S. Dystonic disorders. In Jankovic J, Tolosa E, eds. Parkinson’s disease and movement disorders. 5 ed. Philadelphia: Williams & Wilkins; 2007. p. 331-57.
[5]	Bartolomé FM, Fanjul S, Cantarero S, Hernández J, García- Ruiz PJ. Distonías focales primarias: estudio descriptivo de 205 pacientes. Neurologia 2003; 18: 59-65.
[6]	García-Ruiz Espiga PJ. Distonía laríngea y faríngea. In López del Val LJ, Castro-García C, eds. Toxina botulínica. Aplicaciones terapéuticas en el siglo xxi. 2 ed. Barcelona: Elsevier Masson; 2010. p. 151-6.
[7]	Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1988; 108: 1435-41.
[8]	Ludlow C. Treatment of laryngeal disorders and oromandibular dystonia. In: Toxins 2012: basic science and clinical aspects of botulinum and other neurotoxins. Miami Beach; 2012.
[9]	Jankovic J, Schwartz K. Clinical correlates of response to botulinum toxin injections. Arch Neurol 1991; 48: 1253-6.
[10]	Novakovic D, Waters HH, D’Elia JB, Blitzer A. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. Laryngoscope 2011; 121: 606-12.
[11]	Elmiyeh B, Prasad VM, Upile T, Saunders N, Youl BD, Epstein R, et al. A single-centre retrospective review of unilateral and bilateral Dysport injections in adductor spasmodic dysphonia. Logoped Phoniatr Vocol 2010; 35: 39-44.
[12]	Fulmer SL, Merati AL, Blumin JH. Efficacy of laryngeal botulinum toxin injection: comparison of two techniques. Laryngoscope 2011; 121: 1924-8.
[13]	López-García E, Martínez-Martínez L, Lopez del Val LJ. Distonía laríngea: actualización del tratamiento con toxina botulinica. Revista Española de Trastornos del Movimiento 2013; 5: 20-2.
[14]	Blitzer A. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. Eur J Neurol 2010; 17 (Suppl 1): S28-30.
[15]	García-Ruiz C, Cenjor-Español R, Sánchez-Pernaute R, Astarioa V, Sánchez-Bernados J, García de Yébenes P. Distonía laríngea. Tratamiento con toxina botulínica mediante técnica transcutánea y transoral. Estudio comparativo. Neurologia 1996; 11: 216-9.
[16]	García-Ruiz PJ, Sánchez del Río M, Cenjor-Español C, Sanabria-Brassart J, Sánchez-Bernados V, Astarloa-Gómez R, et al. Disfonía espástica de aducción: clínica y tratamiento. Rev Clin Esp 1998; 198: 156-8.
[17]	Rhew K, Fiedler DA, Ludlow CL. Technique for injection of botulinum toxin through the flexible nasolaryngoscope. Otolaryngol Head Neck Surg 1994; 111: 787-94.
[18]	García-Ruiz PJ, Cenjor-Español C, Sánchez-Bernardos V, Astarloa R, Sanabria J, García de Yébenes J. Botulinum toxin treatment for spasmodic dysphonia: percutaneous versus transoral approach. Clin Neuropharmacol 1998; 21: 196-8.
[19]	Vasconcelos S, Birkent H, Sardesai MG, Merati AL, Hillel AD. Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia. Laryngoscope 2009; 119: 2004-7.
[20]	García-Torres MA, Echeverría-Urabayen A, Contreras A, Carnal-Martín P, García-Ruiz E. Evolución a largo plazo de la dosis de toxina botulínica en las distonías laríngea y cervical. Rev Neurol 2005; 41: 525-6.
[21]	García-Ruiz PJ, Sanz-Cartagena P, Martínez-Castrillo JC, Ares-Pensado B, Avilés-Olmos I, Blázquez-Estrada M, et al. Mitos y evidencias en el empleo de la toxina botulínica: neurofarmacología y distonías. Rev Neurol 2018; 66: 163‑72.
[22]	Brin MF, Blitzer A, Stewart A, Diamond B, Lovelace RE. Botulinum toxin for spasmodic dysphonia: double blind placebo-controlled assessment of dose and technique. Mov Disord 1995; 10: 135-7.

Cite This Article

Plain Text BibTeX RIS

APA Style

Luis Javier López Del Val, José Miguel Sebastián Cortes, Elena Bellosta Diago, Sonia Santos Lasaosa, Paúl Ricardo Vinueza Buitron, et al. (2019). Laryngeal Dystonia, New Approaches for Direct Botulinum Toxin Administration. American Journal of Psychiatry and Neuroscience, 7(3), 52-56. https://doi.org/10.11648/j.ajpn.20190703.11

Copy | Download

ACS Style

Luis Javier López Del Val; José Miguel Sebastián Cortes; Elena Bellosta Diago; Sonia Santos Lasaosa; Paúl Ricardo Vinueza Buitron, et al. Laryngeal Dystonia, New Approaches for Direct Botulinum Toxin Administration. Am. J. Psychiatry Neurosci. 2019, 7(3), 52-56. doi: 10.11648/j.ajpn.20190703.11

Copy | Download

AMA Style

Luis Javier López Del Val, José Miguel Sebastián Cortes, Elena Bellosta Diago, Sonia Santos Lasaosa, Paúl Ricardo Vinueza Buitron, et al. Laryngeal Dystonia, New Approaches for Direct Botulinum Toxin Administration. Am J Psychiatry Neurosci. 2019;7(3):52-56. doi: 10.11648/j.ajpn.20190703.11

Copy | Download

@article{10.11648/j.ajpn.20190703.11,
  author = {Luis Javier López Del Val and José Miguel Sebastián Cortes and Elena Bellosta Diago and Sonia Santos Lasaosa and Paúl Ricardo Vinueza Buitron and Yolanda Lois Ortega and Héctor Valles Varea and Elena López García},
  title = {Laryngeal Dystonia, New Approaches for Direct Botulinum Toxin Administration},
  journal = {American Journal of Psychiatry and Neuroscience},
  volume = {7},
  number = {3},
  pages = {52-56},
  doi = {10.11648/j.ajpn.20190703.11},
  url = {https://doi.org/10.11648/j.ajpn.20190703.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajpn.20190703.11},
  abstract = {To describe our experience in the treatment of laryngeal dystonia (in abduction and adduction), with special emphasis given to the technical aspects (approach procedure, dosage and type of botulinum toxin type A used), as well as treatment response and possible side effects. We conducted a cross-sectional descriptive study of a sample of patients with laryngeal dystonia treated by means of transoral administration of onabotulinumtoxinA or incobotulinumtoxinA over a period of 10 years (2007-2017). Data collected include demographic and clinical variables, treatment response (based on a self-rating scale), the duration of treatment and the appearance of side effects. Sample size: 15 patients (11 women; mean age: 44.06 years) with laryngeal dystonia (mean time since onset of 40 months; 12 patients with dystonia in adduction) and 174 administrations (92% incobotulinumtoxinA; average dosage of 5 U in each vocal cord). The procedure took an average of 11.7 minutes to perform. Response was good in 31% of the procedures and very good in 57.5%. Side effects were recorded in 14.4% of the procedures, although always mild and transitory, with a predominance of dysphagia and dysphonia. In our experience, transoral administration of botulinum toxin type A to treat laryngeal dystonia has proved to be a simple, quick, effective and safe technique.},
 year = {2019}
}

Copy | Download

TY  - JOUR
T1  - Laryngeal Dystonia, New Approaches for Direct Botulinum Toxin Administration
AU  - Luis Javier López Del Val
AU  - José Miguel Sebastián Cortes
AU  - Elena Bellosta Diago
AU  - Sonia Santos Lasaosa
AU  - Paúl Ricardo Vinueza Buitron
AU  - Yolanda Lois Ortega
AU  - Héctor Valles Varea
AU  - Elena López García
Y1  - 2019/08/29
PY  - 2019
N1  - https://doi.org/10.11648/j.ajpn.20190703.11
DO  - 10.11648/j.ajpn.20190703.11
T2  - American Journal of Psychiatry and Neuroscience
JF  - American Journal of Psychiatry and Neuroscience
JO  - American Journal of Psychiatry and Neuroscience
SP  - 52
EP  - 56
PB  - Science Publishing Group
SN  - 2330-426X
UR  - https://doi.org/10.11648/j.ajpn.20190703.11
AB  - To describe our experience in the treatment of laryngeal dystonia (in abduction and adduction), with special emphasis given to the technical aspects (approach procedure, dosage and type of botulinum toxin type A used), as well as treatment response and possible side effects. We conducted a cross-sectional descriptive study of a sample of patients with laryngeal dystonia treated by means of transoral administration of onabotulinumtoxinA or incobotulinumtoxinA over a period of 10 years (2007-2017). Data collected include demographic and clinical variables, treatment response (based on a self-rating scale), the duration of treatment and the appearance of side effects. Sample size: 15 patients (11 women; mean age: 44.06 years) with laryngeal dystonia (mean time since onset of 40 months; 12 patients with dystonia in adduction) and 174 administrations (92% incobotulinumtoxinA; average dosage of 5 U in each vocal cord). The procedure took an average of 11.7 minutes to perform. Response was good in 31% of the procedures and very good in 57.5%. Side effects were recorded in 14.4% of the procedures, although always mild and transitory, with a predominance of dysphagia and dysphonia. In our experience, transoral administration of botulinum toxin type A to treat laryngeal dystonia has proved to be a simple, quick, effective and safe technique.
VL  - 7
IS  - 3
ER  -

Copy | Download

Author Information

Luis Javier López Del Val

Neurology Service, Movement Disorders Unit, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
José Miguel Sebastián Cortes

Servicio de Otorrinolaringología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Elena Bellosta Diago

Neurology Service, Movement Disorders Unit, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Sonia Santos Lasaosa

Neurology Service, Movement Disorders Unit, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Paúl Ricardo Vinueza Buitron

Neurology Service, Movement Disorders Unit, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Yolanda Lois Ortega

Servicio de Otorrinolaringología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Héctor Valles Varea

Servicio de Otorrinolaringología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Elena López García

Neurology Service, Movement Disorders Unit, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Luis Javier López Del Val, José Miguel Sebastián Cortes, Elena Bellosta Diago, Sonia Santos Lasaosa, Paúl Ricardo Vinueza Buitron, et al. (2019). Laryngeal Dystonia, New Approaches for Direct Botulinum Toxin Administration. American Journal of Psychiatry and Neuroscience, 7(3), 52-56. https://doi.org/10.11648/j.ajpn.20190703.11

Copy | Download

ACS Style

Luis Javier López Del Val; José Miguel Sebastián Cortes; Elena Bellosta Diago; Sonia Santos Lasaosa; Paúl Ricardo Vinueza Buitron, et al. Laryngeal Dystonia, New Approaches for Direct Botulinum Toxin Administration. Am. J. Psychiatry Neurosci. 2019, 7(3), 52-56. doi: 10.11648/j.ajpn.20190703.11

Copy | Download

AMA Style

Luis Javier López Del Val, José Miguel Sebastián Cortes, Elena Bellosta Diago, Sonia Santos Lasaosa, Paúl Ricardo Vinueza Buitron, et al. Laryngeal Dystonia, New Approaches for Direct Botulinum Toxin Administration. Am J Psychiatry Neurosci. 2019;7(3):52-56. doi: 10.11648/j.ajpn.20190703.11

Copy | Download

@article{10.11648/j.ajpn.20190703.11,
  author = {Luis Javier López Del Val and José Miguel Sebastián Cortes and Elena Bellosta Diago and Sonia Santos Lasaosa and Paúl Ricardo Vinueza Buitron and Yolanda Lois Ortega and Héctor Valles Varea and Elena López García},
  title = {Laryngeal Dystonia, New Approaches for Direct Botulinum Toxin Administration},
  journal = {American Journal of Psychiatry and Neuroscience},
  volume = {7},
  number = {3},
  pages = {52-56},
  doi = {10.11648/j.ajpn.20190703.11},
  url = {https://doi.org/10.11648/j.ajpn.20190703.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajpn.20190703.11},
  abstract = {To describe our experience in the treatment of laryngeal dystonia (in abduction and adduction), with special emphasis given to the technical aspects (approach procedure, dosage and type of botulinum toxin type A used), as well as treatment response and possible side effects. We conducted a cross-sectional descriptive study of a sample of patients with laryngeal dystonia treated by means of transoral administration of onabotulinumtoxinA or incobotulinumtoxinA over a period of 10 years (2007-2017). Data collected include demographic and clinical variables, treatment response (based on a self-rating scale), the duration of treatment and the appearance of side effects. Sample size: 15 patients (11 women; mean age: 44.06 years) with laryngeal dystonia (mean time since onset of 40 months; 12 patients with dystonia in adduction) and 174 administrations (92% incobotulinumtoxinA; average dosage of 5 U in each vocal cord). The procedure took an average of 11.7 minutes to perform. Response was good in 31% of the procedures and very good in 57.5%. Side effects were recorded in 14.4% of the procedures, although always mild and transitory, with a predominance of dysphagia and dysphonia. In our experience, transoral administration of botulinum toxin type A to treat laryngeal dystonia has proved to be a simple, quick, effective and safe technique.},
 year = {2019}
}

Copy | Download

TY  - JOUR
T1  - Laryngeal Dystonia, New Approaches for Direct Botulinum Toxin Administration
AU  - Luis Javier López Del Val
AU  - José Miguel Sebastián Cortes
AU  - Elena Bellosta Diago
AU  - Sonia Santos Lasaosa
AU  - Paúl Ricardo Vinueza Buitron
AU  - Yolanda Lois Ortega
AU  - Héctor Valles Varea
AU  - Elena López García
Y1  - 2019/08/29
PY  - 2019
N1  - https://doi.org/10.11648/j.ajpn.20190703.11
DO  - 10.11648/j.ajpn.20190703.11
T2  - American Journal of Psychiatry and Neuroscience
JF  - American Journal of Psychiatry and Neuroscience
JO  - American Journal of Psychiatry and Neuroscience
SP  - 52
EP  - 56
PB  - Science Publishing Group
SN  - 2330-426X
UR  - https://doi.org/10.11648/j.ajpn.20190703.11
AB  - To describe our experience in the treatment of laryngeal dystonia (in abduction and adduction), with special emphasis given to the technical aspects (approach procedure, dosage and type of botulinum toxin type A used), as well as treatment response and possible side effects. We conducted a cross-sectional descriptive study of a sample of patients with laryngeal dystonia treated by means of transoral administration of onabotulinumtoxinA or incobotulinumtoxinA over a period of 10 years (2007-2017). Data collected include demographic and clinical variables, treatment response (based on a self-rating scale), the duration of treatment and the appearance of side effects. Sample size: 15 patients (11 women; mean age: 44.06 years) with laryngeal dystonia (mean time since onset of 40 months; 12 patients with dystonia in adduction) and 174 administrations (92% incobotulinumtoxinA; average dosage of 5 U in each vocal cord). The procedure took an average of 11.7 minutes to perform. Response was good in 31% of the procedures and very good in 57.5%. Side effects were recorded in 14.4% of the procedures, although always mild and transitory, with a predominance of dysphagia and dysphonia. In our experience, transoral administration of botulinum toxin type A to treat laryngeal dystonia has proved to be a simple, quick, effective and safe technique.
VL  - 7
IS  - 3
ER  -

Copy | Download